AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
BioPharma Dive49m
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...
Seeking Alpha2h
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
It had an excellent phase 1b dataset with a very strong treatment effect on the primary ... leading on-market brands in ...
Make this one lifestyle change to lower your Parkinson’s disease risk
There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.
The Financial Express9h
Parkinson’s disease clinical research in seven major markets focuses on disease-modifying agents
Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs). With current treatments largely ...
The Pharma Letter18h
Growing emphasis on disease-modifying therapies in Parkinson’s
The Parkinson’s disease (PD) therapeutic landscape is heavily ... With current treatments largely focused on motor symptoms, ...
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
News Medical3d
Traditional Chinese herb shows promise against Alzheimer’s and Parkinson’s
Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.
Yahoo Finance3d
Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents
While Parkinson’s disease (PD) has a large and highly generalised ... the market due to their efficacy against core PD motor ...
AC Immune SA: Promising Pipeline Developments and Robust Financial Health Justify Buy Rating
Leerink Partners analyst Marc Goodman has maintained their bullish stance on ACIU stock, giving a Buy rating yesterday. Marc Goodman has given ...
Business Insider4d
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Pipeline Updates NLRP3 Portfolio VTX3232 (CNS-penetrant NLRP3 Inhibitor): We initiated a Phase 2a trial of VTX3232 in participants with early Parkinson’s disease ... CNS-penetrant NLRP3 inhibitor for ...